famotidine has been researched along with Cardiovascular Diseases in 3 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Famotidine is effective in the prevention of gastric and duodenal ulcers, and erosive oesophagitis in patients taking low-dose aspirin." | 9.14 | Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. ( Bezlyak, V; McCloskey, C; Prasad, R; Taha, AS, 2009) |
| "Famotidine is effective in the prevention of gastric and duodenal ulcers, and erosive oesophagitis in patients taking low-dose aspirin." | 5.14 | Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. ( Bezlyak, V; McCloskey, C; Prasad, R; Taha, AS, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taha, AS | 1 |
| McCloskey, C | 1 |
| Prasad, R | 1 |
| Bezlyak, V | 1 |
| Hiraishi, H | 1 |
| Maeda, M | 1 |
| Sasai, T | 1 |
| Kanke, K | 1 |
| Shimada, T | 1 |
| Celik, I | 1 |
| Stinner, B | 1 |
| Lorenz, W | 1 |
| Dietz, W | 1 |
| Sauer, S | 1 |
| Duda, D | 1 |
| Sitter, H | 1 |
| Junge, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
1 review available for famotidine and Cardiovascular Diseases
| Article | Year |
|---|---|
[Strategy to manage low dose aspirin-induced gastrointestinal injury].
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Famotid | 2011 |
1 trial available for famotidine and Cardiovascular Diseases
| Article | Year |
|---|---|
Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Double-Blind Me | 2009 |
1 other study available for famotidine and Cardiovascular Diseases
| Article | Year |
|---|---|
[Reduction of cardiovascular disorders by preventive perioperative antihistamine administration in general surgery: are the drugs interchangeable?].
Topics: Animals; Cardiovascular Diseases; Cimetidine; Dimethindene; Disease Models, Animal; Drug Evaluation, | 1998 |